Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines

CONCLUSION: Compared to a homologous mRNA booster vaccination, heterologous boosters with NVX-CoV2373 showed lower antibody responses, a higher incidence of new SARS-CoV-2 infections, and fewer adverse events.PMID:37996322 | DOI:10.1016/j.jfma.2023.10.012

Source: J Formos Med Assoc - November 23, 2023 Category: General Medicine Authors: Wang-Huei Sheng Pin-Hung Lin Yu-Chen Cheng Yu-Yun Wu Ming-Ju Hsieh Hung-Chih Yang Sui-Yuan Chang Shan-Chwen Chang Source Type: research